US Medical Device Import Dependence: The $14.5B Trade Deficit

A detailed analysis of US medical device import trade flows from 2013 to 2025, detailing the $14.5B core-device deficit and Section 232 tariff risks.

Sourcing and Supply Chain Risks in US Healthcare

The United States possesses the largest and most technologically advanced medical device market in the world. However, underneath this commercial strength lies a growing supply chain vulnerability: a deep and accelerating reliance on foreign-manufactured medical devices. While the US leads the world in medtech innovation, clinical design, and intellectual property, the physical manufacturing of core medical instruments, consumables, and imaging systems has increasingly shifted overseas.

For healthcare supply chain directors, hospital procurement teams, policy analysts, and commercial directors, understanding the scale of this import reliance is critical. High-tariff environments, national security trade reviews, nearshoring policies, and geopolitical tensions make relying on foreign supply chains a key operational risk.

This analysis provides a detailed, data-driven teardown of US medical device trade flows from 2013 through 2025, based on official statistics from the US Census Bureau. We trace the dramatic flip from a trade surplus to a multibillion-dollar deficit, map the top source countries supplying the US market, break down the specific Harmonized System (HS) product lines driving this reliance, and analyze the commercial and policy risks of the Commerce Department's ongoing Section 232 investigation into medical device import dependence.

The Historical Reversal: From Surplus to a $14.5B Trade Deficit

The most significant structural trend in US medtech trade over the last decade is the complete reversal of the trade balance for core medical devices. In the early 2010s, the US was a net exporter of medical technology, running a multi-billion-dollar trade surplus. By 2017, that surplus vanished, and the trade deficit has since widened significantly.

To analyze this trend, we define the "Core Medical Device" scope using the World Trade Organization (WTO) and United Nations reference frameworks. This scope covers the five primary Harmonized System (HS) 4-digit codes:

HS 9018: Medical, surgical, dental, or veterinary instruments and appliances.
HS 9019: Mechano-therapy, massage, psychological aptitude-testing, ozone, oxygen, aerosol therapy, artificial respiration, or other therapeutic respiration apparatus.
HS 9020: Other breathing appliances and gas masks (excluding protective masks without mechanical parts/replaceable filters).
HS 9021: Orthopedic appliances, crutches, surgical belts/trusses, splints, artificial joints, hearing aids, pacemakers, and other implanted devices.
HS 9022: Apparatus based on the use of X-rays or alpha, beta, or gamma radiations, for medical, surgical, dental, or veterinary uses (including radiography or radiotherapy apparatus).

The table below shows the yearly import and export totals and the resulting trade balance for these core medical devices (HS 9018-9022) from 2013 through 2025:

Year	US Imports (USD)	US Exports (USD)	Net Trade Balance (USD)	Status
2013	33,385,597,743	40,371,061,875	+6,985,464,132	Surplus
2014	35,256,996,646	41,027,364,704	+5,770,368,058	Surplus
2015	36,886,567,879	41,055,737,325	+4,169,169,446	Surplus
2016	39,140,785,253	41,190,349,813	+2,049,564,560	Surplus
2017	41,850,799,829	41,704,712,789	-146,087,040	Deficit
2018	45,978,147,034	44,280,135,382	-1,698,011,652	Deficit
2019	49,588,918,613	46,163,106,972	-3,425,811,641	Deficit
2020	47,406,314,717	42,902,851,416	-4,503,463,301	Deficit
2021	55,616,318,256	47,766,536,756	-7,849,781,500	Deficit
2022	61,377,549,341	51,063,417,801	-10,314,131,540	Deficit
2023	65,127,557,989	55,914,914,863	-9,212,643,126	Deficit
2024	70,281,138,978	55,786,101,357	-14,495,037,621	Deficit
2025	74,075,529,517	56,044,125,804	-18,031,403,713	Deficit

Key Trade Trends:

Deficit Explosion: Between 2013 and 2025, US medical device imports grew by 121.9% (from $33.4B to $74.1B), while US exports grew by only 38.8% (from $40.4B to $56.0B). This difference created a $25.0B swing in the trade balance, shifting from a $7.0B surplus in 2013 to a record $18.0B deficit in 2025.
The Pandemic Shock and Rebound: In 2020, imports declined slightly due to supply chain disruptions and delayed elective surgeries. However, imports surged by 17.3% in 2021 as hospitals restocked and demand returned. This surge accelerated the trade deficit past the $10.0B mark by 2022.

Scope Analysis: HS 9018 vs. HS 9018-9022

A closer look at the trade codes reveals that HS 9018 (Medical Instruments and Appliances) accounts for the largest share of imports, totaling $40.85B in 2024 and $44.01B in 2025.

On an HS 9018-only basis, the trade balance remained in surplus longer, finally flipping to a deficit of -$349M in 2021 before widening to -$3.93B in 2024 and -$7.04B in 2025. Including the other four codes (respiratory therapy, breathing masks, orthopedic implants, and X-ray systems) adds another $30B in imports, widening the total deficit by an additional $11.0B in 2025.

Methodology and Data Caveats

When analyzing international trade statistics, understanding the underlying accounting rules is critical. The trade values reported in this teardown are based on US Census Bureau customs data and are subject to the following definitions and limitations:

Customs Value Definition: The values represent the transaction value of imports and exports as declared to U.S. Customs. Import values are reported as Customs Value, which represents the price actually paid or payable for the merchandise when sold for exportation to the US, excluding U.S. import duties, freight, insurance, and other charges. Export values are reported as FAS (Free Alongside Ship) Value, representing the value of exports at the U.S. port of exportation, including inland freight and insurance.
Exclusion of Retail / Healthcare System Pricing: These trade figures represent the import-export transfer values (often factory-gate or intercompany transfer pricing). They do not represent the final retail market size or the pricing paid by hospitals and healthcare systems, which include distributor markups, logistics costs, sterile packaging, and GPO contract overhead.
Regional Grouping Exclusions: In our country-concentration breakdowns, all regional aggregate groupings used by U.S. Customs (such as OECD, APEC, European Union, NATO, USMCA, and LAFTA) are excluded to prevent double-counting. The "TOTAL FOR ALL COUNTRIES" line is used as the global denominator.
Excluded Medtech Lines: This analysis focuses exclusively on the core device hardware codes (HS 9018-9022). It excludes pharmaceutical products (HS 30), sterile packaging materials, personal protective equipment (PPE, which falls under textile codes), and simple surgical consumables that sit in other commodity sections of the Harmonized Tariff Schedule.

Technical Profile: Code-by-Code Breakdown of HS 9018-9022

To understand where supply vulnerabilities are concentrated, it is helpful to look at the specific Harmonized System (HS) 4-digit categories. Each code represents a distinct product sector with different sourcing dynamics:

1. HS 9018: Medical, Surgical, Dental, or Veterinary Instruments & Appliances

This is the largest code group, accounting for over 59.4% of all core device imports ($44.01B out of $74.08B in 2025). It includes:

Electro-Diagnostic Apparatus (HS 901811-901819): Electrocardiographs (ECGs), magnetic resonance imaging (MRI) systems, ultrasound scanners, and patient monitoring systems. Sourcing is concentrated in Germany, Japan, and China.
Syringes, Needles, and Catheters (HS 901831-901839): Consumables that are highly dependent on high-volume manufacturing in Mexico and Costa Rica.
Other Ophthalmic Instruments (HS 901850): Specialized diagnostic and surgical systems for eye care, with strong imports from Switzerland and Japan.

2. HS 9019: Mechano-Therapy & Therapeutic Respiration Apparatus

This code group covers devices used for physical therapy, breathing assistance, and oxygen delivery. It includes:

Therapeutic Respiration Apparatus (HS 901920): Ventilators, continuous positive airway pressure (CPAP) systems, and oxygen concentrators. Sourcing is concentrated in China and Singapore.

3. HS 9020: Other Breathing Appliances and Gas Masks

This group covers specialized clinical breathing systems and gas masks, excluding simple protective masks. Sourcing is concentrated in Germany and the UK.

4. HS 9021: Orthopedic Appliances and Artificial Body Parts

This code group covers high-value implants and prosthetic systems. It includes:

Artificial Joints and Joint Prostheses (HS 902131): Hip, knee, and shoulder replacements. Sourcing is concentrated in Ireland and Switzerland. Ireland's dominant position reflects the historical concentration of major orthopedic manufacturing hubs (such as Stryker, DePuy Synthes, and Zimmer Biomet) in Galway and Cork, leveraging local technical expertise and corporate tax structures. Switzerland's share focuses primarily on precision dental implants (e.g., Straumann) and high-end spinal hardware.
Hearing Aids (HS 902140): High-volume electronic devices, with major imports from Denmark (William Demant, GN ReSound) and Singapore.
Pacemakers (HS 902150): Implantable cardiac pacemakers, with manufacturing hubs in Ireland and Singapore.

5. HS 9022: Apparatus Based on X-Rays or Radiation

This group covers high-end diagnostic imaging and radiotherapy equipment. Sourcing is concentrated in Germany, Japan, and China.

Top Source Countries: Sourcing Concentrations

US medical device imports are highly concentrated in a small number of key countries. The top five source countries account for over 59.3% of all core device imports, creating concentrated geographical supply risks.

The table below shows the top 10 countries supplying core medical devices (HS 9018-9022) to the US in 2024 and 2025, ranked by 2024 import value:

Rank	Country	2024 Import Value (USD)	2024 Share (%)	2025 Import Value (USD)	2025 Share (%)	Sourcing Profile
1	Mexico	14,838,272,063	21.11%	15,762,052,304	21.28%	USMCA Nearshoring Hub (Juárez, Tijuana)
2	Ireland	8,365,705,978	11.90%	9,173,954,655	12.38%	Corporate Tax & High-End Medtech Cluster
3	Germany	7,339,226,832	10.44%	7,528,152,852	10.16%	Capital Equipment & Imaging Systems
4	Costa Rica	5,633,713,916	8.02%	6,909,102,123	9.33%	Free Trade Zones & Disposable Assemblies
5	China	5,595,773,620	7.96%	4,994,334,593	6.74%	Mass Manufacturing & Commodity Supplies
6	Singapore	3,419,240,654	4.87%	3,543,831,347	4.78%	High-Tech Micro-Optics & Pacemaker Hub
7	Switzerland	3,249,783,009	4.62%	3,207,010,477	4.33%	Precision Instruments & Orthodontics
8	Japan	2,467,665,944	3.51%	2,568,688,377	3.47%	Endoscopes, Optics & Diagnostic Tech
9	Malaysia	1,802,309,335	2.56%	1,794,263,832	2.42%	Rubber/Latex Gloves & Consumables
10	Dominican Republic	1,692,300,376	2.41%	1,775,551,144	2.40%	Free-Zone MedTech Manufacturing (Surgical Instruments)

Bilateral Sourcing Country Details:

Mexico (21.11% in 2024 / 21.28% in 2025): Mexico is the largest exporter of medical devices to the US, sending over $15.76B in goods in 2025. Under the USMCA framework, major manufacturers have established massive maquiladora production plants in border cities like Tijuana and Ciudad Juárez. These plants specialize in labor-intensive device assembly, including surgical kits, catheters, and needles.
Ireland (11.90% in 2024 / 12.38% in 2025): Ireland is a major global hub for medical technology manufacturing, housing clusters in Galway and Dublin. Encouraged by low corporate tax rates, major multinationals manufacture high-value cardiovascular, orthopedic, and active implantable devices (such as drug-eluting stents and pacemakers) in Ireland for export to the US.
Costa Rica (8.02% in 2024 / 9.33% in 2025): Costa Rica is a fast-growing nearshoring destination. Imports from Costa Rica rose from $5.63B in 2024 to $6.91B in 2025, a 22.6% increase. Free trade zones, like the Coyol Free Zone, have attracted massive investment for the manufacturing of disposable components, catheters, and delivery systems.
China (7.96% in 2024 / 6.74% in 2025): China’s share of US medical device imports has started to decline, dropping from $5.60B in 2024 to $4.99B in 2025 (a 10.7% decrease). This decline reflects the impact of tariffs and active supply chain diversification strategies ("China+1"). China remains a major source of medical consumables, diagnostic components, and low-cost hospital equipment, but manufacturers are shifting higher-value assembly lines to USMCA partners.

Nearshoring Trade-Offs: Sourcing Decision Matrix

For MedTech executives evaluating whether to nearshore, offshore, or reshore manufacturing, there is no single "correct" location. Sourcing decisions must balance labor costs, tariff exposure, logistics speed, intellectual property protection, and the local regulatory talent pool.

The matrix below compares the operational trade-offs of the four primary medical device manufacturing hubs:

Sourcing Factor	United States (Reshoring)	Mexico (USMCA Nearshoring)	Costa Rica (Free Zone Hub)	China (Offshore)
Labor Cost	Very High	Low to Moderate	Low to Moderate	Low
Tariff Exposure	None (Domestic)	Low (USMCA compliant)	Low (CAFTA-DR compliant)	High (Section 301 / Section 232)
Logistics Lead Time	Short (1-3 days)	Short (2-5 days road freight)	Moderate (3-7 days air/sea)	Long (20-40 days ocean)
IP Protection	Strongest	Moderate to Strong	Strong	Weak to Moderate
Regulatory Talent	Abundant (FDA-focused)	Growing (COFEPRIS/USMCA)	Good (MDR/FDA experienced)	Large (NMPA-focused)
Grid & Infrastructure	Stable	Variable (Regional power risks)	Stable	High Capacity
Primary Suitability	Low-volume, high-tech, active implants	High-volume sterile assembly, tubing	Catheters, guide wires, disposables	Commodity consumables, raw materials

Sourcing Integration: Mapping Goods Flow to the FDA Global Footprint

A key insight for regulatory and supply chain teams is how these physical goods flows align with the FDA's registered manufacturing establishment database:

Establishment Volume vs. Import Value: While Germany and Ireland account for high import values due to the high unit cost of capital equipment (imaging) and active implants (pacemakers, stents), the total number of physical FDA-registered establishments is much higher in Mexico and China.
The China Footprint: Although China's import value share dropped to 6.74% in 2025, it still holds the second-largest number of FDA-registered foreign facilities. These facilities are primarily registered for Class I devices (consumables, surgical drapes, PPE) or as contract component manufacturers.
The Mexico Integration: Mexico holds a high concentration of Class II registered facilities, reflecting its role as a high-volume assembly hub for catheters, IV administration sets, and surgical instruments.

Intra-Year Trend: China's Steady 2025 Decline

A month-by-month look at China core-device imports (HS 9018-9022) in 2025 shows the diversification story playing out steadily rather than as a pre-tariff front-loading spike. China imports declined over the course of the year, from a January peak of about $550M to roughly $399M in December — a 27.5% drop from the start of the year — with a mid-year trough near $325M in June.

Notably, this pullback materialized before any new Section 232 tariffs were imposed: the Commerce Department only initiated its investigation on September 2, 2025 (announced September 24), and no Section 232 device duties were in force during 2025. In other words, the China share contraction shown in the annual figures (from 7.96% in 2024 to 6.74% in 2025) reflects voluntary "China+1" sourcing shifts and earlier Section 301 tariff pressure, not a one-time stockpiling rush. Manufacturers evaluating China exposure should read the monthly trend as evidence that substitution is already underway — and is likely to accelerate if Section 232 duties land in 2026.

Sourcing and Supply Chain Recommendations: How to Implement Dual-Sourcing

To mitigate these tariff and regulatory risks, medical device manufacturers must transition away from single-source manufacturing. Implementing a dual-sourcing model requires a structured, compliant process to satisfy FDA QMS and pre-market requirements:

Step 1: Perform a Multi-Tier Supply Chain Audit

Map your entire supply chain down to raw materials and component manufacturing. Determine your exposure to high-risk trade jurisdictions for key components (such as printed circuit boards, sensors, and active APIs).

Step 2: Establish Alternative Supplier Relationships

Identify and qualify a secondary supplier located in a low-tariff region (such as a nearshore partner in Costa Rica or Mexico, or a domestic US manufacturer).

Step 3: Validate Alternative Suppliers under ISO 13485

Supplier Qualification: Audit the secondary supplier's QMS and facilities.
Process Validation: For sterile disposables, perform process validation studies (such as EO sterilization validation under ISO 11135 or radiation sterilization validation under ISO 11137) at the secondary site.
Design Controls: Confirm that any component changes do not affect the device's design specifications.

Step 4: Manage FDA Pre-Market Submissions

Letter-to-File: For minor changes that do not affect the device's safety, effectiveness, or intended use, document the supplier change in your internal QMS using a "Letter-to-File."
510(k) Supplement / 30-Day Notice: For significant modifications to materials, manufacturing processes, or sterilization sites for Class II or Class III devices, submit a 510(k) change supplement or a 30-Day Notice to the FDA before marketing the device.

Policy and Sourcing Risks: The Section 232 Investigation

The growing reliance of the U.S. healthcare system on foreign manufacturing has drawn the attention of national security and trade policymakers. On September 24, 2025, the U.S. Commerce Department announced a formal Section 232 national security investigation into the national security risks of medical device imports.

Under Section 232 of the Trade Expansion Act of 1962, the Commerce Department is authorized to investigate whether the quantities or circumstances of an import threaten to impair national security. The investigation features a statutory 270-day timeline to submit a final report and recommendations to the President, which is expected by mid-2026.

Potential Regulatory Outlets of Section 232:

Targeted Tariffs: The investigation could lead to Section 232 tariffs (likely between 10% and 25%) on medical devices and components imported from specific countries, with China being the primary target.
Buy American Mandates: The federal government could expand domestic sourcing mandates for public procurement systems (such as the Veterans Health Administration and Department of Defense), requiring that a higher percentage of medical devices be manufactured in the US.
Reshoring Subsidies: The investigation could support federal funding, tax credits, or subsidies to help companies build domestic manufacturing plants for critical medical supplies (similar to the CHIPS Act for semiconductors).

Frequently Asked Questions

How much does the US import in medical devices, and what is the trade deficit?

In 2025, the US imported $74.08B in core medical devices (HS 9018-9022) and exported $56.04B, resulting in a record trade deficit of $18.03B. This represents a significant increase from the $14.50B deficit recorded in 2024.

Which countries supply most US medical-device imports?

Mexico is the largest exporter of medical devices to the US, accounting for 21.28% ($15.76B) of imports in 2025. It is followed by Ireland (12.38%), Germany (10.16%), Costa Rica (9.33%), and China (6.74%).

What is the difference between HS 9018 and HS 9018-9022 trade figures?

HS 9018 refers specifically to "Medical, Surgical, Dental, or Veterinary Instruments and Appliances," which totaled $44.01B in US imports in 2025. The broader HS 9018-9022 scope includes respiratory therapy devices, breathing masks, orthopedic implants, pacemakers, and X-ray imaging systems, totaling $74.08B in imports.

How exposed are US medical-device imports to China tariffs and the Section 232 investigation?

China exported $4.99B in core medical devices to the US in 2025, representing 6.74% of the import market. These imports are the primary target of the Commerce Department's Section 232 national security investigation (announced September 24, 2025), exposing these supply chains to potential new tariffs of 10% to 25%.

Strategic Summary

The data from the US Census Bureau shows a clear structural trend: the United States has transitioned from a net exporter of medical technology to a nation heavily reliant on foreign-manufactured devices. The trade deficit has widened to a record $18.0B in 2025, driven by nearshoring growth in Mexico and Costa Rica, high-end manufacturing in Ireland, and commodity supplies from China.

As the Section 232 investigation evaluates the security of these supply chains, MedTech companies cannot treat sourcing as a secondary concern. Diversifying supply chains, nearshoring to USMCA partners, and investing in domestic assembly options are essential strategies to ensure compliance, stability, and commercial success in a volatile global market.

Disclaimer: This analysis is based on official trade statistics from the US Census Bureau (covering calendar years 2013 through 2025). Sourcing decisions and regulatory compliance involve legal and operational risks. Manufacturers should consult with qualified supply chain, trade, and legal advisors before making strategic restructuring decisions.

For broader policy context, see our Medical device tariffs and trade-war impact 2026 guide and Medical device supply-chain risk management guide. To compare manufacturing footprint metrics, refer to the FDA device establishment registration: global manufacturing footprint analysis 2026.